科研动态PubMed 摘要

间质性肺疾病中肌少症的临床特征与死亡风险:系统评价与荟萃分析。

PubMed 学科轮询 · 2026-10-05

完整摘要 · 中文译文

目的:肌少症在间质性肺疾病(ILD)中普遍存在,会增加不良结局的风险。本研究旨在明确合并肌少症的ILD患者(ILD-S)的临床特征,并量化肌少症对死亡率的影响。 方法:我们系统检索了PubMed、Embase、Cochrane Library、Web of Science和Scopus中截至2026年9月1日的英文研究,这些研究报告了ILD组与ILD-S组的临床变量(均值±标准差)以及死亡风险校正风险比及95%置信区间(CI)。亚组分析按肌少症诊断标准、ILD亚型和生存时间进行分层。采用Cochran Q和I2统计量评估异质性。进行了敏感性分析(留一法)和发表偏倚评估(Egger检验、剪补法)。 结果:共纳入14项研究,包含1,546名参与者(628例为ILD-S)。与无肌少症的ILD患者相比,ILD-S患者年龄显著更大(WMD = 3.03,95% CI:2.12-3.93),性别-年龄-生理学(GAP)评分更高(WMD = 0.43,95% CI:0.15至0.71),FEV₁/FVC比值更高(WMD = 1.97,95% CI:0.21至3.73,P = 0.03)。相反,ILD-S组在以下指标上数值更低:FEV₁占预计值百分比(WMD = -6.95,95% CI:-9.80至-4.09)、FVC占预计值百分比(WMD = -9.46,95% CI:-12.04至-6.88)、DLCO占预计值百分比(WMD = -5.87,95% CI:-11.68至-0.06)、体重指数(WMD = -1.35,95% CI:-1.89至-0.82)、握力(WMD = -12.80,95% CI:-17.02至-8.58)、6分钟步行距离(WMD = -31.01,95% CI:-60.05至-1.97)以及附 骨骼肌指数(WMD = -1.45,95% CI:-2.15 至 -0.76)。吸烟史方面未观察到显著差异。肌少症与死亡风险增加强烈相关(HR = 2.02,95% CI:1.67 至 2.45),且该关联在不同随访期内保持稳定。敏感性和发表偏倚分析证实了研究结果的稳健性。 结论:ILD-S患者表现出以年龄较大、GAP评分较高、肺功能较差、BMI较低、肌力和肌肉量减少以及死亡率显著升高为特征的特异性特征。系统性地识别这些临床特征可能有助于早期识别ILD-S,并为制定针对性干预措施以改善患者预后提供依据。 系统综述注册:https://inplasy.com/,INPLASY202570030。

完整摘要 · 英文原文

OBJECTIVE: Sarcopenia, prevalent in interstitial lung disease (ILD), increases the risk of poor outcomes. This study aimed to define the clinical characteristics of ILD patients with sarcopenia (ILD-S) and quantify sarcopenia's impact on mortality. METHODS: We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus for English studies up to 1 September 2026 reporting clinical variables (mean ± SD) in ILD vs. ILD-S groups and adjusted hazard ratios with 95% confidence intervals (CI) for mortality risk. Subgroup analyses were stratified by sarcopenia diagnostic criteria, ILD subtype, and survival time. Heterogeneity was assessed using Cochran's Q and I2 statistics. Sensitivity analyses (leave-one-out) and publication bias assessments (Egger's test, trim-and-fill method) were performed. RESULTS: Fourteen studies comprising 1,546 participants (628 with ILD-S) were included. Compared with ILD patients without sarcopenia, those with ILD-S were significantly older (WMD = 3.03, 95% CI: 2.12-3.93), had higher Gender-Age-Physiology (GAP) scores (WMD = 0.43, 95% CI: 0.15 to 0.71), and a higher FEV₁/FVC ratio (WMD = 1.97, 95% CI: 0.21 to 3.73, P = 0.03). Conversely, the ILD-S group showed lower values for FEV₁% predicted (WMD = -6.95, 95% CI: -9.80 to -4.09), FVC% predicted (WMD = -9.46, 95% CI: -12.04 to -6.88), DLCO% predicted (WMD = -5.87, 95% CI: -11.68 to -0.06), body mass index (WMD = -1.35, 95% CI: -1.89 to -0.82), handgrip strength (WMD = -12.80, 95% CI: -17.02 to -8.58), 6-minute walk distance (WMD = -31.01, 95% CI: -60.05 to -1.97), and appendicular skeletal muscle index (WMD = -1.45, 95% CI: -2.15 to -0.76). No significant difference was observed in smoking history. Sarcopenia was strongly associated with increased mortality risk (HR = 2.02, 95% CI: 1.67 to 2.45), and this association remained stable across different follow-up periods. Sensitivity and publication bias analyses confirmed the robustness of the findings. CONCLUSION: Patients with ILD-S exhibit a distinctive profile characterized by older age, higher GAP scores, poorer pulmonary function, lower BMI, reduced muscle strength and mass, and significantly elevated mortality. Systematic recognition of these clinical features may facilitate early identification of ILD-S and inform the development of targeted interventions to improve patient outcomes. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/, INPLASY202570030.

English
Clinical characteristics and mortality risk of sarcopenia in interstitial lung disease: a systematic review and meta-analysis.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界